Subcutaneous trastuzumab?

Roche (SIX:ROG; OTCQX:RHHBY) said EMA's CHMP backed approval of a subcutaneous formulation of Herceptin trastuzumab for HER2-positive breast cancer. The recommendation sent shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) up $1.58 (25%) to $7.95 on Friday; subcutaneous Herceptin is formulated using Halozyme's Enhanze recombinant human hyaluronidase (rHuPH20) drug delivery technology. Roche said subcutaneous administration of Herceptin is less invasive and takes two to five minutes instead of 30-90 minutes with the approved IV administration.

I would propose to try inhalation drug delivery. Or rectal drug administration for trastuzumab - which for sure would be even less invasive.